HeartBeam's FDA-Cleared 3D ECG Technology Featured at ROTH Conference, Signaling Shift in Remote Cardiac Care

HeartBeam Inc. (NASDAQ: BEAT), a medical technology company, was featured in coverage of the 38th Annual ROTH Conference, highlighting its transformative approach to cardiac condition detection and monitoring. The company has developed the first cable-free device capable of collecting electrocardiogram (ECG) signals in three dimensions from non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable use wherever patients are located, delivering actionable heart intelligence to physicians who can then identify cardiac health trends and acute conditions and direct patients to appropriate care outside traditional medical facilities.

The implications of this technology are substantial for cardiac health management, as it enables remote monitoring that could reduce hospital visits and improve early detection of cardiac issues. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, with the 12-Lead ECG synthesis software receiving clearance in December 2025. The company holds over 20 issued patents related to technology enablement, protecting its innovative approach to cardiac monitoring. For more information about the company's technology, visit https://www.heartbeam.com.

The coverage was provided by IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company that created a custom-built portal for the investment community to access information about companies participating in the ROTH Conference. IBN's portal includes summaries of each company along with one-click access to market research tools and helpful website links. The company uses social media and syndicated articles to maximize event visibility, building on more than a decade of experience providing real-time coverage for global events and conferences. To view IBN's coverage of the conference, visit https://events.investorbrandnetwork.com/2026/roth/.

IBN's syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily, ensuring broad visibility for participating companies. For more information about IBN's services, visit https://www.InvestorBrandNetwork.com. The coverage terms and disclaimers are available at http://IBN.fm/Disclaimer. The technology's cleared indications for use, detailing the intended application of HeartBeam's system, can be found at https://www.heartbeam.com/indications.

This conference feature comes at a significant time for HeartBeam, as the company's FDA clearances position it to potentially reshape how cardiac conditions are monitored and managed. The ability to generate clinical-grade 12-lead ECGs outside medical facilities addresses growing needs in telehealth and remote patient monitoring, particularly valuable for patients with mobility limitations, those in rural areas, or individuals requiring frequent cardiac assessment. The technology's portability and cable-free design represent practical advancements over traditional ECG systems, which typically require clinical settings and multiple wired connections.

The financial community's attention through events like the ROTH Conference underscores the market potential for innovative medical technologies that bridge healthcare delivery gaps. As cardiovascular diseases remain leading causes of mortality worldwide, technologies enabling earlier detection and continuous monitoring outside hospital settings could significantly impact patient outcomes and healthcare costs. HeartBeam's participation in this prominent investment conference signals growing recognition of its technology's potential to address these critical healthcare challenges while creating value for stakeholders in the evolving digital health landscape.